

Substitute for form 1449A/PTO
(Revised 10/2001)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 10/008,377
Filing Date November 15, 2001
First Named Inventor Gambacorti-Passerini
Group Art Unit 1642
Examiner Name To be assigned
Attorney Docket Number 45922/241203 (5865-2)

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
MA	1	US-5,529,925	06-25-1996	Morris <i>et al.</i>	
MA	2	US-5,770,421	06-23-1998	Morris <i>et al.</i>	
MA	3	US-6,174,674 B1	01-16-2001	Morris <i>et al.</i>	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

RECEIVED
AUG 05 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T

Examiner
Signature

Michael S. Speck

Date
Considered

12/2/04

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449B/PTO
(Revised 10/2001)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/008,377
Filing Date	November 15, 2001
First Named Inventor	Gambacorti-Passerini
Group Art Unit	1642
Examiner Name	To be assigned
Attorney Docket Number	45922/241203 (5865-2)

RECEIVED
AUG 05 2002
TECH CENTER 1600/2900

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
MS	4	DREXLER, H., <i>et al.</i> , "Pathobiology of NPM-ALK and Variant Fusion Genes in Anaplastic Large Cell Lymphoma and Other Lymphomas," <i>Leukemia</i> , 2000, pp. 1533-1559, Vol. 14, Macmillan Publishers Ltd.	
	5	MORRIS, S., <i>et al.</i> , "Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkin's Lymphoma," <i>Science</i> , March 1994, pp. 1281-1284, Vol. 263 (5151), American Association for the Advancement of Science, USA.	
	6	MORRIS, S., <i>et al.</i> , "Sequence Correction," <i>Science</i> , January 1995, pp. 316-317, Vol. 267(5196), American Association for the Advancement of Science, USA.	
	7	PASSONI, L., <i>et al.</i> , "ALK as a Novel Lymphoma-Associated Tumor Antigen: Identification of 2 HLA-A2.1-Restricted CD8 ⁺ T-cell Epitopes," <i>Blood</i> , March 2002, pp. 2100-2106, Vol. 99(6), The American Society of Hematology, USA.	
MS	8	PULFORD, K., <i>et al.</i> , "Immune Response to the ALK Oncogenic Tyrosine Kinase in Patients with Anaplastic Large-Cell Lymphoma," <i>Blood</i> , August 2000, pp. 1605-1607, Vol. 96(4), The American Society of Hematology, USA.	
	9	PASSONI, L., <i>et al.</i> , "In Vitro Induction of Primary HLA Class I-Restricted Immune Response Against ALK Kinase," Experimental Lymphoma Therapy, Poster Board No. 509, Session II, Abstract #1459.	

Examiner Signature	<i>Michael Spunk</i>	Date Considered	12/2/04
-----------------------	----------------------	--------------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.